Biopharmaceutical startup JHL Biotech has opened its new biosimilars manufacturing facility in China, the company announced last week.
The facility in Wuhan features world’s first modular manufacturing solution based on single-use bioprocessing technology, which was delivered by GE Healthcare in just 18 months.
JHL will use GE Healthcare’s KUBio manufacturing solution to produce biosimilars and monoclonal antibodies for late-stage clinical trials and commercial supply. The facility will also provide process development and manufacturing services for JHL’s global customers.
KUBio is a prefabricated, cGMP-compliant facility and process solution designed for scalable and cost-efficient manufacturing.
Racho Jordanov, CEO and co-founder of JHL Biotech, said: “JHL Biotech’s mission is to make quality medicines affordable to more people, and we believe one of the greatest areas of need is in Asia. It was important to us to establish our scale-up manufacturing capacity in Asia with a manufacturing facility in China capable of producing biologics to a world-class standard.
“JHL’s new facility in Wuhan has the same standardized GE FlexFactory technology as our existing site in Taiwan, which allowed us to quickly scale up to a capacity of 2,000 liters. JHL Biotech now has the largest volume of single-use cell culture capacity in Asia with the opening of our new facility in Wuhan.”
According to JHL, the biosimilars market in China is growing rapidly. A report from Frost & Sullivan predicted that it will be worth approximately $350 million by 2019, up from $44 million in 2009.
